Certara offers predictive science and informatics solutions that enable cross-disciplinary and translational approaches to drug development.

PBPK Modeling and Simulation

Simcyp is now part of Certara, continues delivering leading-edge science, accelerating drug discovery and development for its Consortium of member pharma companies. More about Simcyp on

Simcyp Population-based Simulator Predict drug absorption and disposition in virtual patient populations, including paediatrics. Learn more at

Consultancy for a broad spectrum of DMPK issues, including optimal design for metabolic drug-drug interaction studies, interpretation of data and prediction of in vivo ADME from in vitro studies Learn more at

Interactive workshops and courses cover the concepts of model-based drug development with focus on incorporating population variability into mechanistic prediction of PK and modelling of PK-PD Explore upcoming events at

Key Publications Simcyp actively publishes the results of its research in the form of conference abstracts and peer-reviewed papers. Explore citations and published articles

Bookmark and Share

Simcyp Paediatric Simulator

The Simcyp Paediatric Simulator allows pharmacokinetic behaviour to be modelled in neonates, infants and children. This provides valuable information relevant to first-time dosing decisions and the design of paediatric clinical studies.

The Simulator includes a full physiologically-based pharmacokinetic (PBPK) model together with extensive libraries on demographics, developmental physiology and the ontogeny of drug elimination pathways. It allows population variability in pharmacokinetics to be simulated over any age range and potential drug-drug interactions to be quantified. Predictions can be made either from in vitro data or from adult in vivo values by retrograde modelling.

Simcyp Paediatric is a module within the Simcyp Population-based Simulator which is licensed to members of the Simcyp Consortium of leading pharmaceutical and biotechnology companies.